Assenagon Asset Management S.A. Has $78.09 Million Position in Halozyme Therapeutics, Inc. $HALO

Key Points

• Assenagon Asset Management increased its Halozyme position by 4,578.9% in the second quarter, ending with 997,643 shares worth approximately $78.1 million. Institutional investors collectively own 97.79% of the company.
• Halozyme reported record second-quarter results, with adjusted EPS of $2.28 and revenue of $481 million, up 47.7% year over year and well above analyst expectations. Management also raised its 2026 guidance, including projected non-GAAP EPS of $8.65–$9.00.
• Analyst sentiment is broadly positive, but valuation concerns remain: several firms raised their price targets and the consensus rating is “Moderate Buy,” while the stock’s $103.12 price was above MarketBeat’s $91.20 consensus target and some analysts’ targets.

Assenagon Asset Management S.A. increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 4,578.9% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 997,643 shares of the biopharmaceutical company's stock after purchasing an additional 976,321 shares during the period. Assenagon Asset Management S.A. owned approximately 0.84% of Halozyme Therapeutics worth $78,086,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in HALO. Norges Bank bought a new position in shares of Halozyme Therapeutics during the 4th quarter worth about $128,201,000. William Blair Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics during the 4th quarter worth approximately $124,031,000. Voloridge Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $77,587,000. Qube Research & Technologies Ltd bought a new stake in shares of Halozyme Therapeutics during the second quarter valued at approximately $51,295,000. Finally, Mizuho Markets Americas LLC increased its holdings in Halozyme Therapeutics by 270.8% in the 4th quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company's stock valued at $85,382,000 after buying an additional 926,526 shares during the period. Institutional investors own 97.79% of the company's stock.

Key Stories Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Record Q2 results beat expectations: Halozyme reported adjusted earnings of $2.28 per share, above the roughly $1.79-$1.82 consensus, while revenue rose 48% year over year to $481 million versus estimates near $402 million. Royalty revenue increased 50% to $308 million. Halozyme reports record second quarter 2026 results
• Positive Sentiment: 2026 guidance was raised: Management now expects revenue of $1.835 billion-$1.910 billion, royalty revenue of $1.220 billion-$1.245 billion, adjusted EBITDA of $1.225 billion-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS range is above the approximately $8.02 analyst consensus. Halozyme Q2 earnings beat estimates
• Positive Sentiment: Commercial momentum expanded: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, exceeding its full-year goal of three. The agreements support the company’s royalty-driven platform model and broaden future revenue opportunities.
• Positive Sentiment: Analyst sentiment improved: Leerink Partners upgraded HALO to “outperform” with a $110 price target. HC Wainwright raised its target to $115 and retained a “buy” rating, while TD Cowen increased its target to $105 and also rated the stock “buy.”
• Neutral Sentiment: Analyst views remain mixed at the elevated valuation: Citizens JMP raised its target to $93 with a “market outperform” rating, and Wells Fargo lifted its target to $95 while maintaining “equal weight.” Both targets remain below the recent trading level, suggesting some analysts see limited near-term upside.

Analyst Ratings Changes

Several research firms have issued reports on HALO. HC Wainwright increased their price objective on Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a "buy" rating in a research note on Friday. Morgan Stanley lowered their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating on the stock in a report on Tuesday, May 12th. TD Cowen increased their target price on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a "buy" rating in a research report on Friday. Wall Street Zen raised shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Saturday. Finally, Citigroup restated a "market outperform" rating on shares of Halozyme Therapeutics in a research report on Friday. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $91.20.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $103.12 on Friday. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The business has a 50-day moving average of $76.48 and a 200-day moving average of $71.47. The stock has a market capitalization of $12.23 billion, a price-to-earnings ratio of 30.78, a PEG ratio of 0.36 and a beta of 0.85. Halozyme Therapeutics, Inc. has a fifty-two week low of $61.22 and a fifty-two week high of $103.30.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping analysts' consensus estimates of $1.79 by $0.49. The business had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 232.11%. The firm's revenue for the quarter was up 47.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the sale, the chief executive officer owned 767,780 shares of the company's stock, valued at $51,886,572.40. This represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the firm's stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the transaction, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 72,477 shares of company stock worth $5,102,643. 2.50% of the stock is owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source